2
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Sarcoma
1
Endocrine
1
Conditions
Neoplasms
19
Endometrial Neoplasms
15
Ovarian Neoplasms
11
Carcinoma, Non-Small-Cell Lung
10
Neoplasm Metastasis
7
Squamous Cell Carcinoma of Head and Neck
6
Uterine Cervical Neoplasms
5
Head and Neck Neoplasms
5
Breast Neoplasms
5
Rectal Neoplasms
4
Pancreatic Neoplasms
4
Melanoma
4
Lung Neoplasms
4
Colonic Neoplasms
4
Fallopian Tube Neoplasms
3
Colorectal Neoplasms
3
Triple Negative Breast Neoplasms
2
Stomach Neoplasms
2
Recurrence
2
Osteosarcoma
2
Multiple Myeloma
2
Locally Advanced Rectal Cancer (LARC)
2
Carcinoma, Renal Cell
2
Carcinoma, Neuroendocrine
2
Carcinoma, Hepatocellular
2
Carcinoma
2
Vulvar Neoplasms
1
Vaginal Neoplasms
1
Uterine Neoplasms
1
Turcot syndrome
1
Interventions
Mitotane
10
Cisplatin
9
pembrolizumab
7
Doxorubicin
6
Etoposide
5
Specimen Handling
4
Nivolumab
4
Magnetic Resonance Spectroscopy
4
relacorilant
3
cabozantinib
3
Cytoreduction Surgical Procedures
3
sodium thiosulfate
2
cixutumumab
2
cemiplimab
2
camrelizumab
2
apatinib
2
Trastuzumab
2
Suramin
2
Radiotherapy
2
Ipilimumab
2
Dichlorodiphenyldichloroethane
2
Cyclophosphamide
2
tipifarnib
1
pegfilgrastim
1
milademetan
1
lenvatinib
1
iodophenyl metomidate
1
gossypol acetic acid
1
fludarabine phosphate
1
entinostat
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Adrenocortical Carcinoma
×
dostarlimab
×
Clear all
NCT06333314
2025-12-02
Pan-MSI-ACSE
UNICANCER
Phase 2
Recruiting
120 enrolled